Publication:
Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study

Research Projects

Organizational Units

Journal Issue

Abstract

Objectives To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.Method One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9.Results A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 +/- 11.1 years and 6.9 +/- 6.5 years, respectively. The most commonly used TNF alpha inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit.Conclusions The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment.

Description

Keywords

Certolizumab pegol, Clinical-response, Disease-activity, Double-blind, Phase-iii, Golimumab, Safety, Trial, Multicenter, Etanercept, Anti-TNF, ACR20/50/70, DAPSA28, DAS28, Psoriatic arthritis, Work disability, Rheumatology

Citation

Collections


Metrikler

Search on Google Scholar


Total Views

0

Total Downloads

0